Upgrade to SI Premium - Free Trial

Form 3 Cellebrite DI Ltd. For: Mar 18 Filed by: Armon Ronnen

March 18, 2026 8:23 AM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Armon Ronnen
(Last) (First) (Middle)
94 SHLOMO SHMELZER ROAD
(Street)
PETAH TIKVA 4970602
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, par value NIS 0.00001 ("Ordinary Shares") 277,844 (1) (2) (3) (4) (5)
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock options (6) 02/15/2032 Ordinary Shares 60,606 6.6 D
Stock options (7) 02/13/2033 Ordinary Shares 80,808 4.95 D
Stock options (8) 03/19/2034 Ordinary Shares 43,440 11.51 D
Stock options (9) 03/19/2034 Ordinary Shares 43,440 11.51 D
Explanation of Responses:
1. Includes 29,320 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on February 14, 2023, of which 7,330 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.
2. Includes 24,030 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 2,670 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.
3. Includes 27,768 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 2,136 vest on each of March 20, 2026 and every three months thereafter through March 20, 2029.
4. Includes 5,341 Ordinary Shares that are represented by performance share units ("PSUs") that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028. Each PSU represents a contingent right to receive one Ordinary Share of the Issuer upon vesting and settlement.
5. Includes 5,341 Ordinary Shares that are represented by PSUs that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028.
6. These stock options are fully vested and exercisable.
7. Of these stock options, 60,608 are fully vested and exercisable and 5,050 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027.
8. Of these stock options, 19,005 are fully vested and exercisable and 2,715 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.
9. Of these stock options, 15,204 are fully vested and exercisable and 2,172 vest on each of March 20, 2026 and every three months thereafter through March 20, 2029.
Remarks:
Chief Products & Technologies Officer
/s/ Ronnen Armon 03/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings